HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile

AIDS Research and Human Retroviruses

Volumn 30, Issue 11, 2014, Pages 1089-1098

  Forsell, Mattias N E ^a,b   McKee, Krisha ^a   Feng, Yu ^a   Mascola, John R ^a   Wyatt, Richard T ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY VRC01; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MACROMOLECULE; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EVALUATION STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; TRANSGENIC RABBIT; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; IMMUNOLOGY; MACROMOLECULE; RABBIT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; MACROMOLECULAR SUBSTANCES; PROTEIN BINDING; RABBITS;

EID: 84932182619     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0104     Document Type: Article

References (34)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361(23):2209-2220.
2. Gottardo R, Bailer RT, Korber BT, et al.: Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013;8(9):e75665.
3. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-1286.
4. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-289.
5. Burton DR, Desrosiers RC, Doms RW, et al.: HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5(3):233-236.
6. Parren PW, Marx PA, Hessell AJ, et al.: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75(17): 8340-8347.
7. Vaine M, Wang S, Liu Q, et al.: Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 2010;5(11):e13916.
8. Labrijn AF, Poignard P, Raja A, et al.: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003;77(19): 10557-10565.
9. Binley JM, Wrin T, Korber B, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004;78(23):13232-13252.
10. Scheid JF, Mouquet H, Feldhahn N, et al.: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009;458(7238):636-640.
11. Wu X, Yang ZY, Li Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329(5993):856-861.
12. Veazey RS, Shattock RJ, Pope M, et al.: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9(3):343-346.
13. Li Y, Migueles SA, Welcher B, et al.: Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007;13(9):1032-1034.
14. Li Y, Svehla K, Louder MK, et al.: Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009;83(2):1045-1059.
15. Verkoczy L and Diaz M: Autoreactivity in HIV-1 broadly neutralizing antibodies: Implications for their function and induction by vaccination. Curr Opin HIV AIDS 2014;9(3): 224-234.
16. Martinelli E, Cicala C, Van Ryk D, et al.: HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2007;104(9):3396-3401.
17. Sandgren KJ, Smed-Sorensen A, Forsell MN, et al.: Human plasmacytoid dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4 for antigen presentation. J Immunol 2013;191(1):60-69.
18. Douagi I, Forsell MN, Sundling C, et al.: Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein im-munogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 2010;84(4):1683-1695.
19. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, and Sub-ramaniam S: Molecular architecture of native HIV-1 gp120 trimers. Nature 2008;455(7209):109-113.
20. Mao Y, Wang L, Gu C, et al.: Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci USA 2013;110(30):12438-12443.
21. Snyder BW, Vitale J, Milos P, et al.: Developmental and tissue-specific expression of human CD4 in transgenic rabbits. Mol Reprod Dev 1995;40(4):419-428.
22. Forsell MN, Dey B, Morner A, et al.: B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog 2008;4(10): e1000171.
23. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, and Sodroski J: Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76(9):4634-4642.
24. Feng Y, McKee K, Tran K, et al.: Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem 2012;287(8):5673-5686.
25. Dey B, Svehla K, Xu L, et al.: Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009; 5(5):e1000445.
26. Decker JM, Bibollet-Ruche F, Wei X, et al.: Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005;201(9):1407-1419.
27. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, and Sodroski J: Identification of individual human immunode-ficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990;64(12):5701-5707.
28. Sundling C, Li Y, Huynh N, et al.: High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med 2012;4(142): 142ra196.
29. DeVico A, Fouts T, Lewis GK, et al.: Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit im-munogens. Proc Natl Acad Sci USA 2007;104(44):17477-17482.
30. Xiang SH, Kwong PD, Gupta R, et al.: Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002;76(19): 9888-9899.
31. Dosenovic P, Chakrabarti B, Soldemo M, et al.: Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J Immunol 2009;183(5):3373-3382.
32. Sundling C, Forsell MN, O'Dell S, et al.: Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010;207(9):2003-2017.
33. Ching L and Stamatatos L: Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop. J Virol 2010;84(19):9932-9946.
34. Sanders RW, Derking R, Cupo A, et al.: A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013;9(9): e1003618.